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human-specific astroglial cells in the (A) CAI, (B) CA2 and 
( C) dentate gyrus, measured bilaterally on four to six alternate 
sections for each mouse. U p<0.01 indicates a significant 
difference within saline treated group (Student's unpaired 
METHOD OF BIASING IMPLANTED HUMAN 
NEURAL STEM CELLS AWAY FROM 
DIFFERENTIATION INTO GLIAL CELLS BY 
(+)PHENSERINE TO MODULATE THE 
CONCENTRATION OF SOLUBLE ~APP IN 
TISSUE OR CSF 
RELATED APPLICATIONS 
5 t-test); (D) Correlation of APP protein levels with number of 
GFAP+/Brdu+ cells in the hippocampus of 6-7 months old 
APP23 mice that received saline only. Each point corre-
sponds to average APP protein levels and number of GFAP+/ 
This application claims the benefit of U.S. Provisional 10 
Patent application Ser. No. 60/704,319, filed Aug. I, 2005, 
incorporated herein by reference. 
BACKGROUND 
Brdu+ cells in the CAI, CA2 and dentate gyrus regions of 
each individual mouse. (Linear regression r=0.47; p<0.05). 
FIG. 5. Differentiation of HNSCs into neuronal cells in 
vivo after treatment with either saline or ( + )-phenserine (25 
mg/kg). (a-d) Representative fluorescent immunohis-
tochemical images in the CAI hippocampal region of 6-7 
15 months old APP23 and non-transgenic mice 6 weeks after 
HNSCs transplantation. Sections were double-immunofluo-
rescence stained with ~III-tubulin (green) and BrdU (red) 
markers for neural cells and donor cells, respectively. All 
Patients currently suffering from neurodegenerative con-
ditions such as Alzheimer's and Parkinson's have limited 
treatment options. Conventional drug therapy helps delay or 
reduce the symptoms of disease but is unable to restore com-
plete functionality of the brain or repair damaged tissue. 20 
Through stem cell-based therapies, scientists aim to trans-
plant cells in order to regenerate damaged tissue and restore 
proper function. However, the inventors have realized that the 
ability of implanted cells to migrate properly to a desired 
locus and to differentiate into a desired cell type are funda- 25 
mental and vital obstacles for implementing in cell transplan-
tation therapy. The inventors have made important strides in 
addressing such issues. 
nuclei were counterstained by DAPI (blue). 
FIG. 6. Differentiation of HNSCs into neuronal cells in 
vivo after treatment with either saline or ( + )-phenserine (25 
mg/kg). (a-d) Representative fluorescent immunohis-
tochemical images in the CA2 hippocampal region of 6-7 
months old APP23 and non-transgenic mice 6 weeks after 
HNSCs transplantation. Sections were double-immunofluo-
rescence stained with ~III-tubulin (green) and BrdU (red) 
markers for neural cells and donor cells, respectively. All 
nuclei were counterstained by DAPI (blue). 
FIG. 7. Immunohistochemical analysis of transplanted 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. (A) Relative protein levels of total sAPP (22Cl I) 
and GFAP in the hippocampus of6-8 months oldAPP23 and 
non-transgenic mice that were treated with either saline or 
( + )-phenserine (25 mg/kg) respectively, for 2 weeks. ** 
p<0.01 and * p<0.05 indicates significantly different from 
saline treated. t p<0.05 indicates significantly different 
within saline treated group (Student's unpaired t-test). All 
values are expressed as mean±S.E.M. from 3-4 independent 
experiments. (B) Representative Western blots for Sapp and 
GFAP from saline (s) and (+)-phenserine (p) treatedAPP23 
and non-transgenic mice. 
30 HNSC expressing immunoreactivity for neuronal marker 
~III-tubulin and Brdu after 6 weeks differentiation in hippoc-
ampal and cortical regions of 6-7 months old APP23 and 
non-transgenic mice that were treated with either saline or 
phenserine (25 mg/kg). All values are expressed as 
35 mean±S.E.M. (n=6-7 within each group), and were obtained 
by averaging counts of immuno-reactive human-specific neu-
ronal cells in the (A) CAI, (B) CA2, (C) dentate gyrus and (D) 
motor and (E) sensory cortex, measured bilaterally on four to 
six alternate sections for each mouse. * * * p<0.0001; * p<0.05 
40 indicates a significant difference from saline treated (Stu-
dent's unpaired t-test). 
FIG. 2. Differentiation of HNSCs into astroglial cells in 
vivo after treatment with either saline or ( + )-phenserine (25 
mg/kg). (a-d) Representative fluorescent immunohis- 45 
tochemical images in the CAI hippocampal region of 6-7 
months old APP23 and non-transgenic mice 6 weeks after 
HNSCs transplantation. Sections were double-immunofluo-
rescence stained with GFAP (green) and BrdU (red) markers 
for astroglia cells and donor cells, respectively. All nuclei 50 
were counterstained by DAPI (blue). 
DETAILED DESCRIPTION 
In reviewing the detailed disclosure which follows, and the 
specification more generally, it should be borne in mind that 
all patents, patent applications, patent publications, technical 
publications, scientific publications, and other references ref-
erenced herein are hereby incorporated by reference in this 
application, in their entirety to the extent not inconsistent with 
the teachings herein. 
It is important to an understanding of the present invention 
to note that all technical and scientific terms used herein, 
unless defined herein, are intended to have the same meaning 
as commonly understood by one of ordinary skill in the art. 
The techniques employed herein are also those that are known 
to one of ordinary skill in the art, unless stated otherwise. For 
purposes of more clearly facilitating an understanding the 
invention as disclosed and claimed herein, the following defi-
FIG. 3. Differentiation of HNSCs into astroglial cells in 
vivo after treatment with either saline or ( + )-phenserine (25 
mg/kg). (a-d) Representative fluorescent immunohis-
tochemical images in the CA2 hippocampal region of 6-7 55 
months old APP23 and non-transgenic mice 6 weeks after 
HNSCs transplantation. Sections were double-immunofluo-
rescence stained with GFAP (green) and BrdU (red) markers 
for astroglia cells and donor cells, respectively. All nuclei 
were counterstained by DAPI (blue). 60 nitions are provided. 
FIG. 4. Immunohistochemical analysis of transplanted 
HNSC expressing immunoreactivity for GFAP and Brdu after 
6 weeks differentiation inhippocampal regions of 6-7 months 
old APP23 and non-transgenic mice that were treated with 
either saline or phenserine (25 mg/kg). All values are 65 
expressed as mean±S.E.M. (n=6-7 within each group), and 
were obtained by averaging counts of immunoreactive 
The administration of cholinesterase inhibitors such as 
(-)Phenserine is believed to be useful in treating cognitive 
disorders such as Alzheimers disease. The potential positive 
effects of administering cholinesterase inhibitors is some-
what offset by undesired and potentially dangerous side 
effects. The administration of cholinesterase inhibitors is 
believed to increase acetylcholine levels in the brain, which is 
US 9,095,573 B2 
3 
depleted in anAlzheimers brain, and therefore increase activ-
ity of the brain's cholinergic system. However, such inhibi-
tors produce a toxicity caused by their inhibition of acetyl-
cholinesterase, such as nausea, vomiting, dizziness, tremors, 
bradycardia, inter alia. Some in the field have tried using an 5 
enantiomer of ( - ) phenserine in an effort to avoid some of 
these undesired side effects. For example, Greig et al., U.S. 
Patent Pub. 2004/0024043 AND 2004/0138282 discuss use 
4 
uses of increased potency cells obtained from the taught 
methods, and in particular, the implantation of stem cells for 
different therapeutic treatments of neurological trauma and 
degenerative conditions. The third patent application is 
directed to the use of certain compounds to stimulate prolif-
eration and migration of stem cells. Those skilled in the art 
will readily appreciate that the cells of the present invention 
could be obtained, or their effectiveness enhanced, by com-
bining with the teachings of the aforementioned patent appli-of ( +) phenserine which lacks cholinesterase activity, avoid-
ing the side effects of the cholinesterase inhibitors. Grieg et 
al. demonstrated that administration of ( +) phenserine dra-
matically reduces ~APP levels in the brain. It is believed that 
this lowering of ~APP levels in the brain in turn results in 
lowered A~ levels. A~ is believed to induce progressive neu-
rodegenerative condition leading to loss of memory charac-
terized by the appearance of senile plaques that are primarily 
composed of an A~ and neurofibrillary tangle aggregates. 
10 cations, without undue experimentation. Human neural stem 
cells may be derived from embryonic or adult allogenic or 
autogenic sources and may be genetically engineered to be 
biased to differentiate into a desired phenotype. See for 
example, co-pending U.S. application Nos. 60/621,483, 
15 60/621,902, and 60/621,901 
The focus of the Greig et al. studies is the dramatic reduc-
tion of A~, thus, one is lead to strive toward shutting down 
~APP production as much as possible. The inventors postu- 20 
late that controlling ~APP rather than shutting down ~APP 
levels is what is critical in optimizing brain conditions to 
prevent progression of Alzheimer's disease. Indeed, the 
inventors surmise that the shutting down ~APP production is 
counterproductive; it may put a patient in a transient 25 
improved state, but it will ultimately lead to a worsened state 
of progression of the disease. This is discussed further below. 
The brain harbors stems cells which require signals to 
migrate to an area of need. ~APP is a primary inducer of stem 
cell migration in the brain. The inventors have found that a 30 
high concentration of ~APP in the brain will bias differentia-
tion of neural stem cells into astrocytes. Thus, one of the 
potential pathological bases for the progression of Alzhe-
imer's disease is the exhaustion of endogenous stem cell 
reserves in Alzheimer's brains which are differentiated into 35 
an over abundance of astrocytes as opposed to new neurons. 
The inventors have also discovered that controlling ~APP 
levels in the brain to optimal levels is also critical when 
implementing cell transplantation strategies. As with endog-
enous sources of stems cells, transplanted stem cells will also 40 
be biased to produce undesired glial producing cells, such as 
astrocytes. Thus, in one embodiment, the invention pertains 
to a method of transplanting human neural stem cells in the 
brain in conjunction with a regimen of ( + )phenserine treat-
ment. ( + )Phenserine may be administered a week to several 45 
weeks prior to cell transplantation, and/or a week to weeks 
subsequent to cell transplantation. Though generating an 
environment of the brain with reduced levels of ~APP is 
desired for cell transplantation therapies, generating 
extremely low levels of ~APP will inhibit cell mobilization 50 
which is needed for implanted cells to migrate to their needed 
location, grow and differentiate in the desired phenotype. 
Accordingly, in a preferred embodiment, ( + )phenserine is 
administered in conjunction with human neural stem cell 
transplantation according to a regimen (dosage amount and 55 
frequency) such that the site of transplantation comprises an 
average ~APP concentration of about 0.5 to about 40 nano-
grams of ~APP per milliliter of tissue or cerebrospinal fluid. 
Preferably, the regimen is such that an average ~APP concen-
tration of about 1 to 10 nanograms/ml is maintained over a 60 
period of at least one day, two days, one week, two weeks, one 
month, two months, three months, four months, five months, 
six months or one year. 
U.S. Patent Application Nos. 2003/0219898, 2003/ 
0148513, and 2003/0139410 are incorporated by reference to 65 
the extent they are not inconsistent with the teachings herein. 
The first two of these patent applications describe multiple 
EXAMPLE 1 
Modulation of Human Neural Stem Cell 
Differentiation in APP23 Transgenic Mice by 
Phenserine Treatment 
Materials and Methods 
Human Neural Stem Cell Cultures. 
HNSCs originally isolated from 9 weeks old fetal cortical 
tissue were purchased from Bio Whittaker (Walkersville, 
Md.) and the cells were expanded and passaged in a serum-
free culture medium, as described in detail previously (Bran-
nen and Sugaya, 2000). Briefly, HNSCs were cultured in 20 
ml serum-free supplemented growth medium consisting of 
Ham's F12/DMEM (Gibco, Burlington, ON), EGF (20 
ng/ml, R & D Systems), FGF (20 ng/ml, R & D Systems, 
Minneapolis, Minn.), B27 (1 :50, Gibco ), heparin (5 µg/ml, 
Sigma, St. Louis, Mo.) and antibiotic-antimycotic mixure 
(1: 100, Gibco) at 3 7° C. in a 5% humidified incubation cham-
ber (Brannen and Sugaya, 2000). Prior to transplantation, 
HNSCs were incubated with 3 µM bromo-deoxyuridine 
(BrdU, Sigma) for 48 hr to label cell nuclei to distinguish 
them from the host cells. 
Animals. 
APP23 mice, expressing the 751-amino acid human amy-
loid-precursor protein (hAPP751) with the Swedish double 
mutation (K670N, M671L) driven by the neuron-specific 
murine Thy-I-promoter (Sturchler-Pierrat et al., 1997) were 
received as a gift from Novartis Pharma Ltd., (Switzerland), 
and employed to breed a colony of experimental animals by 
backcrossing to C57 /BL6 mice. Mixed genotype groups were 
housed in standard mouse cages with access to food and water 
ad libitum, constant room temperature and humidity, during a 
12/12 hr light/dark cycle. Genotypes were confirmed by PCR 
(Calhoun et al., 1999). In all experiments wild-type litter-
mates served as controls. All animal experimental procedures 
were carried out in compliance with National Institutes 
Health Guidelines for Care and Use of Laboratory Animals, 
and approved by the Animal Research Committee (protocol 
00-24) at the University of Central Florida. 
( + )-Phenserine Treatment. 
A total of 55 age and sex-matched APP23 (n=30) and 
wild-type (n=25) mice (ages ranged from 4-7 months) were 
administered with either ( + )-phenserine (25 mg/kg/day, i.p.) 
or 0.9% saline (control) for 14 consecutive days. Animals 
were subsequently divided into two groups that were either 
sacrificed following 14 days treatment (n= 17 APP23 and 
n=13 wild-type, respectively) or received transplantation of 
HSNC into the lateral ventricle (n=13 APP23 mice and n=12 
wild-type, respectively). ( + )-Phenserine or saline injection 
was continued once a day for 1 week after a 2-day recovery 
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from transplantation surgery. All animals were sacrificed 
within 12 hrs of receiving the final dose of ( + )-phenserine or 
0.9% saline by an overdose of a 1: 1 mixture ofKetamine (100 
mg/kg) and Xylazine (20 mg/kg), and transcardially perfused 
with phosphate buffer (PBS). Brains were removed, dissected 5 
into the hippocampus and cortex, and tissue samples were 
maintained on dry ice and stored at -80° C. until Western 
blotting and PCR experiments were performed. For the group 
of transplanted animals, these were transcardially perfused 
with PBS and 4% paraformaldehyde (pH 7.4). Brains were 10 
removed and post-fixed for 8-12 h in 4% paraformaldehyde, 
and cryoprotected in 20% sucrose-PBS overnight. The brains 
were subsequently cut on a cryostat (20 µm coronal sections) 
and kept in PBS at 4 ° C. for fluorescent immunohistochemi-
6 
rabbit IgG, Jackson Immunoresearch Laboratories Inc, West 
Grove, Pa.) at RT for 1 hr. Three final washes of 15 min in 
duration each were performed. Signals were visualized by 
incubation of the membranes in ECL Plus reagents (Amer-
sham Biosciences, Buckinghamshire, UK), exposed to Hyper 
Performance Chemiluminescence film (Amersham) and 
developed according to standard procedures. The films were 
scanned and the optical density of each specific band relative 
to ~-actin, was analyzed by the public domain NIH Image J 
software (version 1.33u) and expressed in means±SD from 
experiments performed in triplicate. 
Real Time RT-PCRAnalysis. 
Total RNA from hippocampal and cortical tissues from 
each animal treated with either ( + )-phenserine or saline was 
cal analysis. 
Animal Surgery and Transplantation. 
15 isolated with Trizol reagent (Invitrogen) according to the 
manufacturer's protocol. One µg of the total RNA was tran-
scribed into cDNA with reagents from the iScript cDNA 
Synthesis Kit (Bio-Rad). Complete reaction mixture was pre-
Animals were deeply anesthetized with a 1: 1 mixture of 
Ketamine ( 100 mg/kg) and X y lazine (20 mg/kg) and mounted 
onto a stereotaxic apparatus (ASI Instrument, USA). For 
transplantation, approximately 105 cells HNSCs were sus- 20 
pended in 10 µl PBS, and slowly injected into the right lateral 
ventricle of each mouse using a 25 µl Hamilton gastight 
syringe (Hamilton, Reno, Nev., USA) with a 22-gauge bev-
eled needle attached. The tip was held in place for 3 min 
during delivery and left in place for another 3 min after each 25 
injection. Intra-ventricular injection minimizes disruption of 
brain tissue and may leverage endogenous signals ( eg. 
chemokines released by microglia in response to damage) 
that might affect stem cell migration. In reference to the 
bregma, the coordinates used for implantation were as fol- 30 
lows: anterior posterior (A/P)-0.6 mm; medial lateral (M/L) 
+1.0 mm; dorsal/ventral (D/V) +2.4 mm. No immune sup-
pression was utilized and all efforts were made to minimize 
the number of animals used and their suffering by observation 
of maintained body weight and also by monitoring incisions 35 
for swelling and proper healing of the incision site. 
Protein Isolation and Western Blot Analysis. 
Western blot analysis was performed to analyze effect of 
( + )-phenserine on the relative APP and GFAP protein expres-
sion in APP23 and control mice. Dissected tissues from the 40 
cortex and the hippocampus of ( + )-phenserine and saline 
treated animals were homogenized in ice-cold lysis buffer 
containing 1 % NP40, 150 mM NaCl, 50 mM Tris (pH 8.0), 
and 1 x protease inhibitor cocktail (Roche Diagnostics, India-
napolis, Ind.). The homogenates were centrifuged and 45 
washed twice at 12,000x g for 10 min at 4 ° C. and the super-
natants were used for protein quantification by the Bradford 
method using Bio-Rad Protein Assay Dye Reagent (Bio-Rad, 
Hercules, Calif.). Samples were denatured in a sample buffer 
(Invitrogen, Carlsbad, Calif.) for 10 min at 70° C. Fifteen µg 50 
of protein was loaded per well and proteins separated under 
non-reducing conditions on NuPAGE 4-12% Novex Bis-Tris 
gels (Invitrogen) for 60 min at 200 V, and then blotted onto 
PVDF membranes (Bio-Rad) for 120 min at 30 V. For the 
detection of APP and GFAP protein, membranes were 55 
blocked in phosphate buffered saline, pH 7.4, and 0.05% 
Tween-20 (PBS-T), with 5%non-fatdriedmilkand thereafter 
incubated with mouse monoclonal anti-Alzheimer precursor 
protein (22Cl 1) A4 antibody (1: 1000, Chemicon, Temecula, 
Calif.) and rabbit anti-GFAP antibody (1: 1000, Promega, 60 
Madison, Wis.) in PBS-T containing 1 % non-fat dried milk 
over night at 4° C. To standardize the amount of protein 
loaded on to each gel, the polyclonal rabbit anti-B-actin anti-
body (1:1000, Cell Signaling Technology, Danvers, Mass.) 
was used. The membranes were washed three times for 15 65 
min in PBS-T and then incubated with secondary horseradish 
peroxidase-conjugated antibodies (anti-mouse IgG and anti-
pared according to kit instructions and incubated at 42° C. for 
30 min, 85° C. for 5 min and then cooled. Relative quantifi-
cation with Real-time PCR was determined using the MyiQ 
Real-Time PCR Detection System Software (Bio-Rad), and 
reactions were performed in a thermal iCycler using the Bio-
Rad MyiQ IQ SYBR Green Supermix (Bio-Rad) according to 
the following conditions; denaturation of cDNA for 5 min at 
94° C.; amplification ( 40 cycles) for 30 sec at 94° C., anneal-
ing at 56° C. for 30 sec, and extension at 72° C. for 30 sec, 
with a final extension at 72° C. for 5 min. The authenticity of 
the PCR products was verified by melt-curve analysis at 55° 
C. to 95° C. for 10 sec and cooling for 5 min at 20° C. The 
primers used in this experiment were: APP (forward) 
5'-GAGACACCTGGGGATGAGAA-3' (SEQ ID NO: 1, 
APP (reverse) 5'-CTTGACGTTCTGCCTCTTCC-3' (SEQ 
ID NO: 2, ~-actin (forward) 5'-CACACTGTGCCCATC-
TACG-3' (SEQ ID NO: 3, ~-actin (reverse) 5'-CCATCTCT-
TGCTCGAAGTCC-3' (SEQ ID NO: 4). The PCR efficien-
cies of the PCR reactions were evaluated from dilution series 
of cDNA in real-time PCR. Threshold cycle (Ct) values were 
used to plot a standard curve in which Ct decreased in linear 
proportion to the log of the template copy number. A com-
parative Ct method was then utilized to determine relative 
expression ratios of APP and ~-actin mRNA in samples. 
Flourescent Immunohistochemistry. 
Free floating coronal brain sections (20 µm) were washed 
briefly in PBS, denatured with IM HCl for 20 min and neu-
tralized with PBS for 30 min at room temperature (RT), in 
order to increase the accessibility of the anti-BrdU antibody 
to the BrdU incorporated in the cell nuclei. The sections were 
then blocked in PBS containing 0.25% TritonX-100 and 3% 
Normal Donkey Serum for 1 hr and incubated with sheep 
polyclonal anti-BrdU (1:1000, Abeam, Cambridge, Mass.) 
and mouse IgG2b anti-human ~III-Tubulin, clone SDL3D10 
(1 :2000, Sigma), or rabbit IgG anti-human Glial Fibrillary 
Acidic Protein (GFAP 1:500, Sigma) diluted in PBS contain-
ing 0.25% TritonX-100 and with 3% Normal Donkey Serum 
overnight at 4 ° C. After rinsing in PBS-T, sections were 
incubated with corresponding secondary antibodies (1:500) 
conjugated with fluorescein (FITC) or rhodamine (TRITC) 
(Jackson IR Laboratories, Inc.) for 2 hr at RT. After a final 
wash in PBS-T, sections were mounted and cover slipped 
with Vectashield with DAPI (Vector Laboratories, Inc., Bur-
lingame, Calif.) for fluorescent microscopic observation. 
Microscopy and Analysis of Differentiation. 
Cell migration and differentiation in transplanted mice 
(n=6-7 mice in each group) were quantified by unbiased 
bilateral counts of number of BrdU positive cells expressing 
either the neuronal marker, ~III-Tubulin, or the glial marker, 
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GFAP, in the molecular and granule layers ofhippocampal 
CAI, CA2 and dentate gyrus, and motor and sensory regions 
8 
Effects of ( + )-phenserine on Glial Differentiation ofTrans-
planted HNSCs in APP23 Mice 
of the cerebral cortex using a Leica DMRB fluorescent micro-
scope at 400x magnification. Microscopic images were taken 
with anAxiocam digital camera (Carl Zeiss) mounted on the 5 
DMRB and processed using the QIMAGING with Q Capture 
software (Qimaging Corporation).An average of 4-6 sections 
were counted for each animal. The number of transplanted 
cells counted in each section were averaged for each side so 
that the final numbers represented the mean neuron or astro- 10 
cyte number per sampling area. 
Six weeks after implantation, fluorescent double label 
immunohistochemistry was employed to identify cells 
derived from transplanted HNSCs (BrdU-labeled) and to 
examine their differentiation into either neural or glial cells. 
Also, we sought to determine whether the ( + )-phenserine-
induced effects on APP could influence the differentiation 
fate of transplanted HNSCs. Transplanted HNSCs survived in 
vivo and an extensive number of cells exhibiting characteris-
tic astroglial morphologies, and co-expressing BrdU with the 
astrocytic marker for human GFAP (BrdU+/GFAP+) were 
observed in the molecular and granule layers of the hippoc-
ampal CAI, CA2 (FIGS. 2-3), and the dentate gyrus (data not 
shown). Typically, APP23 mice showed more pronounced 
immunoreactivity for BrdU+/GFAP+ compared to controls. 
Data and Statistical Analysis. 
Data are presented as mean±SEM of different experiments 
and differences between groups were analyzed with a two- 15 
tailed Student's t-test. A simple linear regression test (Graph-
Pad PRISM 3.0) was used to evaluate possible correlations. The cells expressing BrdU+/GFAP+ in hippocampal regions 
were counted and the results were expressed as the average 
number ofBrdU+/GFAP+ cells per region for each treatment 
Results 
Reduced APP protein expresion following ( + )-phenserine 
treatment 
To investigate the effects of ( + )-phenserine on APP protein 
expression, Western blot analysis was performed on cortical 
and hippocampal tissues fromAPP23 mice treated with either 
20 group (FIG. 4A-C). APP23 mice showed significantly 
(p<0.01) more BrdU+/GFAP+ double immuno-positive cells 
compared to that of wild-type mice (FIG. 4A-C). Following 
( + )-phenserine treatment, a marked reduction (ranging from 
28% to 40%) in number of BrdU+ /GFAP+ double immuno-( + )-phenserine (25 mg/kg, i.p. /day for 14 days) or saline. In 
agreement with our previous findings, APP23 mice showed 
significantly (p<0.05) higher levels of APP (-2-fold) com-
pared to that of controls (FIG. 1). Following ( + )-phenserine 
treatment, a significant decrease (-3-fold) in APP protein 
expression was observed in the hippocampus of APP23 mice 
(p<0.01) compared to saline treated mice (FIG. 1). No sig-
nificant change in APP protein expression was observed 
between ( + )-phenserine treated and saline treated wild-type 
mice (FIG. 1). Although APP protein expression was also 
reduced in the cerebral cortices ofAPP23 and wild-type mice 35 
after ( + )-phenserine treatment, these reductions did not reach 
statistical significance (p>0.05, data not shown). 
25 positive cells was observed in hippocampal regions of APP23 
mice (FIG. 4A-C), indicating that ( + )-phenserine could 
reduce the glial differentiation caused by APP over-expres-
sion. No significant differences in the number of Brdu+; 
GFAP+ double immuno-positive cells were observed in the 
30 hippocampus of wild-type mice after ( + )-phenserine treat-
ment (FIG. 4A-C). There was a significant correlation 
(p<0.05; linearregressionr=0.47) between number ofBrdu+; 
GFAP+ double immuno-positive cells and APP protein 
expression in the hippocampus of APP23 mice (FIG. 4D). 
Effects of ( + )-phenserine on Neuronal Differentiation of 
Transplanted HNSCs in APP23 Transgenic Mice 
Examination of neuronal differentiation of transplanted 
HNSCs was also performed inAPP23 and wild-type mice that 
were treated with ( + )-phenserine or saline. The number of 
Reduced GFAP protein expression following ( + )-
phenserine treatment 
Previous studies have reported that APP overexpression in 
APP23 mice is also associated with marked gliogenesis in the 
brains of these mice (Sturchler-Pierrat and Staufenbiel, 
2000). Therefore, we also measured GFAP (glial cell marker) 
expression in these mice and investigated whether treatment 
with ( + )-phenserine could alter expression levels. We 
observed that APP23 mice had significantly (p<0.05) higher 
(-2.5-fold) GFAP protein expressed in the hippocampus 
compared to that of wild-type mice. Following ( + )-
phenserine treatment (25 mg/kg, i.p. /day for 14 days), GFAP 
expression was significantly (p<0.05) reduced (-1.5-fold) in 
APP23 mice (FIG. 1). No significant changes were observed 
between ( + )-phenserine treated and saline treated wild-type 
mice (FIG. 1). GFAP protein expression in the cerebral cor-
tices of APP23 and wild-type mice was similar and no sig-
nificant change was observed after ( + )-phenserine treatment 
(data not shown). 
Effect of ( + )-phenserine on APP Gene Expression in 
APP23 Mice 
To investigate whether the ( + )-phenserine-induced reduc-
tion of APP protein expression in APP23 mice was mediated 
at the transcriptional level, quantitative real-time PCR analy-
sis was performed on cortical and hippocampal tissues from 
treated animals. However, no significant changes were 
observed in APP gene expression following ( + )-phenserine 
treatment in both APP23 and wild-type mice (data not 
shown), indicating that ( + )-phenserine reduces APP levels by 
post-transcriptional processing. 
40 cells co-expressing BrdU with the neuronal marker for human 
~-III tubulin (BrdU+/~-III tubulin+) were counted in the 
molecular and the granule layers of the hippocampal CAI and 
CA2, the dentate gyrus, and in the pyramidal layers of the 
somatosensory and the motor cortex. To exclude the possibil-
45 ity that measured neuronal immunoreactivity was also detect-
ing non-neuronal and endogenous neurons in mouse that 
were not derived from the transplanted HNSCs, we stained in 
parallel experiments sections with the neuronal marker NeuN 
and a human nuclear specific antibody. Similar results were 
50 obtained for NeuN staining as with ~-III tubulin and BrdU, 
thus verifying that the differentiated cells were of human 
origin (data not shown). 
HNSCs transplanted into APP23 and wild-type mice dif-
ferentiated into ~-III tubulin immuno-positive cells. The 
55 BrdU+ /~-III tubulin+ cells within the CAI and the CA2 region 
had large pyramidal morphologies (FIG. 5-6), whereas those 
in the dentate granule layer displayed a small ovoid appear-
ance typical for dentate granule neurons (data not shown). In 
the somatosensory and motor cortical regions, BrdU+/~-III 
60 tubulin+ cells exhibited both pyramidal and non-pyramidal 
morphologies (data not shown). 
We anticipated a reduced neuronal differentiation of trans-
planted HNSCs in saline treatedAPP23 mice, based on earlier 
findings in vitro where more glial differentiation of HNSCs 
65 was observed after treatment with sAPP (Kwak et al., 2006). 
Fewer BrdU+/~-III tubulin+ double immuno-positive cells 
were detected in the motor and somatosensory cortex of 
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APP23 mice in comparison to wild-type mice (FIG. 7D-E), 
whereas no significant difference in the number ofBrdU+/~­
III tubulin+ double immuno-positive cells was observed in the 
hippocampal regions of APP23 mice compared to wild-type 
mice (FIG. 7A-C). Interestingly, we observed a significant 
increase (ranging from 32% to 112%) in the number of 
BrdU+/~-III tubulin+ double immuno-positive cells in the 
hippocampal CAI and CA2 (p<0.0001), and the motor and 
the somatosensory cortex (p<0.05) of APP 23 mice after 
( + )-phenserine treatment compared to the number of cells 
10 found in APP23 treated with saline (FIG. 7A-B, D-E). A 
significant (p<0.05) increase ( 40%) in the number of BrdU+ I 
~-III tubulin+ cells was observed only in the CAI hippocam-
pal region of wild-type mice treated with ( + )-phenserine 
(FIG. 7A). 
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The invention claimed is: 
1. A method of biasing implanted neural stem cells away 
from differentiation into glial cells, said method comprising 
administering to a patient in need thereof human neural stem 
cells to said patient at a site of transplantation, said site of 
transplantation being in the brain of said patient; and admin-
istering a regimen of ( +) phenserine, wherein said ( +) 
phenserine is administered according to a regimen such that 
the site of transplantation comprises an average soluble ~APP 
concentration of about 0.5 to about 40 nanograms of soluble 10 
~APP per milliliter of tissue or cerebrospinal fluid. 
2. The method of claim 1, wherein the human neural stem 
cells are administered by injecting the human neural stem 
cells with a syringe, inserting the human neural stem cells 
with a catheter or surgically implanting the human neural 15 
stem cells. 
3. The method of claim 2 wherein the human neural stem 
cells are injected with a syringe into a brain cavity that is 
fluidly-connected to a target area of neurological deficit. 
4. The method of claim 2 wherein the human neural stem 20 
cells are inserted with a catheter into a brain cavity that is 
fluidly-connected to a target area of neurological deficit. 
5. The method of claim 2 wherein the human neural stem 
cells are surgically implanted into a brain cavity that is flu-
idly-connected to a target area of neurological deficit. 25 
6. The method of claim 1, wherein said ( +) phenserine is 
administered according to a regimen such that an average 
~APP concentration of about 1 to 10 nano grams/ml of tissue 
or cerebrospinal fluid is maintained over a period of at least 
one day, two days, one week, two weeks, one month, two 30 
months, three months, four months, five months, six months 
or one year. 
* * * * * 
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